Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HyloTouch Softip Patch is a transdermal delivery system containing the alkaloid **hyoscine** (also known as **scopolamine**), developed and marketed by **Sparsha Pharma International**. The product is indicated for the prevention of nausea and vomiting associated with **motion sickness**. The patch utilizes Sparsha's proprietary 'Softip' technology, which is designed to improve patient comfort and ensure consistent, sustained drug delivery through the skin. Hyoscine acts as a competitive antagonist at muscarinic acetylcholine receptors, particularly in the vestibular system and the vomiting center of the central nervous system, thereby inhibiting the cholinergic signaling that triggers motion-induced emesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyoscine.